Policy / Pricing MFN affecting Swiss medicines access, says Interpharma PharmaphorumPharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.Read full story pharminent August 13, 2026 (Last updated: August 21, 2026) Pharmaphorum Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access. Read full story Post navigation Previous: Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps RemainNext: PTC takes a chance on Sangamo’s Fabry disease gene therapy Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026